Law360, New York (August 14, 2009, 6:03 PM ET) -- A federal judge has cleared the way for multidistrict litigation claiming that Novartis Pharmaceutical Corp.’s bone cancer drugs Aredia and Zometa cause a condition involving jaw deterioration, shooting down two of the drugmaker’s key summary judgment bids.
Among dozens of rulings handed down Thursday, Chief Judge Todd J. Campbell of the U.S. District Court for the Middle District of Tennessee denied Novartis’ summary judgment motions arguing that it provided adequate warnings and that the plaintiffs’ general-causation experts should be excluded.
While the decisions were issued in...
Judge Greenlights Aredia Cases Against Novartis
To view the full article, take a free trial now.
